Windlas Biotech Ltd. benchmarking: Performance to industry peers

Financial

	Windlas Biotech	Sakar Healthcare	Ind-Swift Labs.
Operational Metrics
Financials
5 yr Average ROE	10.64 %	8.14 %	14.7 %
5yr average Equity Multiplier	1.39	1.76	2.17
5yr Average Asset Turnover Ratio	1.07	0.45	0.66
5yr Avg Net Profit Margin	7.49 %	10.03 %	16.17 %
Price to Book	3.06	5.54	1.26
P/E	26.71	58.98	42.24
5yr Avg Cash Conversion Cycle	-12.87 Days	18.72 Days	15.71 Days
Inventory Days	39.91 Days	51.79 Days	103.91 Days
Days Receivable	72.81 Days	53.06 Days	105.66 Days
Days Payable	93.99 Days	115.64 Days	107.02 Days
5yr Average Interest Coverage Ratio	42.87	4.85	21.19
5yr Avg ROCE	16.39 %	8.92 %	12.09 %
5yr Avg Operating Profit Margin	12.11 %	24.94 %	14.94 %
5 yr average Debt to Equity	0.05	0.49	0.91
5yr CAGR Net Profit	30.97 %	10.38 %	n/a
5yr Average Return on Assets	7.71 %	4.54 %	11.49 %
Shareholdings
Promoter Holding	61.9 %	52.86 %	42.99 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.48 %	-7.86 %	0.99 %
Change in Mutual Fund Holding (3 Yrs)	-3.56 %	0.0	0.0

	Windlas Biotech	Sakar Healthcare	Ind-Swift Labs.
Product Wise Break-Up	Product Wise Break-Up CDMO 71.67 Trade Generics & OTC 22.75 Exports 5.58 Loan Licensing 0 Export 0 Pharmaceuticals 0	Product Wise Break-Up Exports 0 Loan Licensing 5.0 Pharmaceuticals 0 CDMO 22.0 Trade Generics & OTC 0 Export 73.0	Product Wise Break-Up Exports 0 Loan Licensing 0 Pharmaceutical 100.0 CDMO 0 Trade Generics & OTC 0 Export 0
Location Wise Break-Up	Location Wise Break-Up India 95.68 International 0 India 0 Others 4.32	Location Wise Break-Up International 55.48 India 0 Others 44.52	Location Wise Break-Up International 0 India 27.72 Others 72.28
Acute vs Chronic	Acute vs Chronic Chronic & Sub-Chronic 59.0 Acute 41.0	-	-
Segment Wise Break-Up	Segment Wise Break-Up Pharmaceutical 100.0	-	-